Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months
- 9 April 1994
- journal article
- clinical trial
- Published by Elsevier BV in The Lancet
- Vol. 343 (8902), 881-886
- https://doi.org/10.1016/s0140-6736(94)90007-8
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary AngioplastyNew England Journal of Medicine, 1994
- Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial.Circulation, 1993
- Pharmacological Approaches to the Prevention of Restenosis Following AngioplastyDrugs, 1993
- Analysis of coronary angioplasty practice in the United States with an insurance-claims data base.Circulation, 1993
- Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein llb/llla in patients undergoing elective coronary angioplastyCoronary Artery Disease, 1993
- Migration of smooth muscle and endothelial cells. Critical events in restenosis.Circulation, 1992
- Clinical trials of restenosis after coronary angioplasty.Circulation, 1991
- The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplastyJournal of the American College of Cardiology, 1991
- A paradigm for restenosis based on cell biology: Clues for the development of new preventive therapiesJournal of the American College of Cardiology, 1991
- A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex.JCI Insight, 1985